Masimo 'disappointed' in Q2 results, confirms slashed guidance
Masimo shares fell this morning after the company shared second-quarter results that included slashed 2023 guidance.
Stay updated with breaking news from Sam Eiber. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Masimo shares fell this morning after the company shared second-quarter results that included slashed 2023 guidance.
Masimo shareholders voted to oust two members of the device developer's board after a heated battle by Politan Capital Management.
Despite a negative reaction following a major buy in the insulin delivery space, analysts still back Insulet (Nasdaq:PODD) stock to perform.
Operator: Good day, and welcome to the Senseonics First Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode.
Wearable cardiac monitor developer iRhythm disclosed its third subpoena in more than two years from federal investigators.